A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Phase 3

Completed

Brief Summary: The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).

Recruitment & Eligibility

Inclusion Criteria

Male or female patients who completed the INBUILD® trial as planned and who did not prematurely discontinue blinded treatment.
Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
Women of childbearing potential (WOCBP)1 must continue to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method, for 28 days prior to and 3 months after nintedanib administration. A list of contraception methods meeting these criteria is provided in the patient information

Exclusion Criteria

Any disease that may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of the INBUILD® trial. However, patients may qualify for participation even though exclusion criteria may have been met during the course of participation in INBUILD®, if the investigator's benefit-risk assessment remains favourable.
Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
Patient not compliant in parent trial (INBUILD®), with trial medication or trial visits, according to investigator's judgement.
Previous enrolment in this trial. Further exclusion criteria apply.

Arm && Interventions

Group	Intervention	Description
Nintedanib	Nintedanib	Patients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (\~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Any Adverse Events	From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.	Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment.

Secondary Outcome Measures

Name	Time	Method

Locations (121): University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
University of California Los Angeles
🇺🇸
Los Angeles, California, United States
University of California Davis
🇺🇸
Sacramento, California, United States
National Jewish Health
🇺🇸
Denver, Colorado, United States
Yale University School of Medicine
🇺🇸
New Haven, Connecticut, United States
Pulmonary and Sleep of Tampa Bay
🇺🇸
Brandon, Florida, United States
University of Florida College of Medicine
🇺🇸
Jacksonville, Florida, United States
Emory University
🇺🇸
Atlanta, Georgia, United States
University of Chicago
🇺🇸
Chicago, Illinois, United States
Loyola University Medical Center
🇺🇸
Maywood, Illinois, United States
Scroll for more (111 remaining)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States